Back to News
Market Impact: 0.6

Celestica Outperforms Industry Year to Date: Reason to Buy the Stock?

CLSJBLFLEXAMDAVGOMSFTGOOGLGOOGAMZNORCLMETATSLANVDA
Artificial IntelligenceTechnology & InnovationCompany FundamentalsCorporate EarningsCorporate Guidance & OutlookProduct LaunchesAnalyst EstimatesAnalyst Insights
Celestica Outperforms Industry Year to Date: Reason to Buy the Stock?

Celestica (CLS) has significantly outperformed its industry and peers with a 103.4% year-to-date stock surge, driven by robust demand in its Connectivity & Cloud Solutions (CCS) segment, which reported 28% Q2 2025 revenue growth to $2.07 billion, notably an 82% increase in its Hyperscaler Portfolio Solutions (HPS) business fueled by 800G networking switches. The company is strategically expanding its presence in the rapidly growing AI infrastructure market, introducing new offerings and projecting 30% CCS revenue growth for 2025. Strong liquidity, evidenced by $313.8 million in cash and $119.9 million in free cash flow in Q2 2025, further underpins its growth trajectory, despite its current premium valuation at 30.91x forward P/E.

Analysis

Celestica, Inc. (CLS) has demonstrated significant market outperformance, with its stock surging 103.4% year-to-date, substantially exceeding the 57.5% growth of its industry and the gains of peers Jabil (45.2%) and Flex (30%). This performance is underpinned by fundamental strength, particularly within its Connectivity & Cloud Solutions (CCS) segment, which reported a 28% year-over-year revenue increase to $2.07 billion in the second quarter. The primary driver is the Hyperscaler Portfolio Solutions (HPS) business, which grew an impressive 82% year-over-year to $1.2 billion, fueled by accelerating demand for 800G networking switches essential for AI infrastructure. The company is strategically positioned to capitalize on the AI market, projected to grow at a 30.4% CAGR through 2030, with management forecasting 30% revenue growth for the CCS segment in 2025. Financially, Celestica exhibits robust health; as of Q2 2025, it reported a strong current ratio of 1.44 (versus the industry's 1.15) and a remarkable 82.8% year-over-year increase in free cash flow to $119.9 million. This operational efficiency supports its growth initiatives. However, this strong outlook is reflected in its valuation, as the stock trades at a premium forward P/E of 30.91, compared to the industry average of 22.59, a key consideration for investors.

AllMind AI Terminal